RxDoctor Payments Data

Ashley Chappell

Adult Health · Bourbonnais, ILNPI 1194070458

Payments from drug & device makers

$545in general payments, 2019–2025

Across 23 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$144
  • Lundbeck LLC$79
  • Teva Pharmaceuticals USA, Inc.$57
  • AbbVie$56
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$50
  • Otsuka America Pharmaceutical, Inc.$47
  • plus $112 from 4 others

What the payments were for

  • Food & beverage$545100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$545 in reported general payments places this provider in the 60th percentile of 553 adult health providers in Illinois.

See all adult health providers in Illinois

Medicare billing

Part B allowed, 2024
$56,081
Medicare patients
254
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl165$232,376
IngrezzaValbenazine Tosylate13$118,999
Abilify MaintenaAripiprazole24$63,581
RexultiBrexpiprazole17$23,514
Paliperidone ErPaliperidone75$5,114
Aripiprazole22$3,074
Atomoxetine Hcl16$2,522
Quetiapine Fumarate158$1,640
Vilazodone Hcl14$1,416
Duloxetine Hcl73$1,388
Olanzapine110$1,122
Quetiapine Fumarate ErQuetiapine Fumarate16$1,012
Mirtazapine100$981
Gabapentin89$946
Alprazolam95$857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$56$232,376165 claims
Neurocrine Biosciences, Inc.Ingrezza$42$118,99913 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$47$87,09641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 553 adult health providers in Illinois.

Other adult health in Bourbonnais

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →